Global Hospital Injectable Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hospital Injectable Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Injectables refer to drug delivery system which acts as an alternative to oral drugs. As injectables are rapidly inserted into the human body using a syringe, they bypass the first-pass metabolism. In tablet form, some of the drugs become ineffective as they get dismantled in the stomach owing to the digestive enzymes. Generic injectables are pharmaceutical drugs that are bio-equivalent of a branded injectable in terms of dosage, strength, performance, intended use, side-effects and route of administration.
Hospital Injectable Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hospital Injectable Drugs market is projected to reach US$ 56330 million in 2034, increasing from US$ 40410 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2034. Demand from Oncology and Anesthesia are the major drivers for the industry.
In 2019, North America held the main share in global hospital injectable drugs market,with the propotion of 35%,Europe followed loosely ,at the propotion of 33%.
Hospira (Pfizer Inc.) occupied the biggest global hospital injectable drugs market share(13%), Fresenius Kabi followed closely at the propotion of 13%, Baxter and Sichuan Kelun Pharmaceutical also played a virtal role in the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hospital Injectable Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Hospira (Pfizer Inc.)
Baxter
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Otsuka
B.Braun
JW Life Science
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Sichuan Kelun Pharmaceutical
Cisen Pharmaceutical
Shijiazhuang No. 4 Pharmaceutical
Shandong Hualu Pharmaceutical
CR Double-Crane
Segment by Type
Generic Sterile Injectables
Sterile Intravenous (IV) Solutions
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hospital Injectable Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Hospital Injectable Drugs introduction, etc. Hospital Injectable Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Hospital Injectable Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Hospital Injectable Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hospital Injectable Drugs market is projected to reach US$ 56330 million in 2034, increasing from US$ 40410 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2034. Demand from Oncology and Anesthesia are the major drivers for the industry.
In 2019, North America held the main share in global hospital injectable drugs market,with the propotion of 35%,Europe followed loosely ,at the propotion of 33%.
Hospira (Pfizer Inc.) occupied the biggest global hospital injectable drugs market share(13%), Fresenius Kabi followed closely at the propotion of 13%, Baxter and Sichuan Kelun Pharmaceutical also played a virtal role in the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hospital Injectable Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Hospira (Pfizer Inc.)
Baxter
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Otsuka
B.Braun
JW Life Science
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Sichuan Kelun Pharmaceutical
Cisen Pharmaceutical
Shijiazhuang No. 4 Pharmaceutical
Shandong Hualu Pharmaceutical
CR Double-Crane
Segment by Type
Generic Sterile Injectables
Sterile Intravenous (IV) Solutions
Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hospital Injectable Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Hospital Injectable Drugs introduction, etc. Hospital Injectable Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Hospital Injectable Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices